A second-generation TKI should always be used as initial therapy for CML

Research output: Contribution to journal › Article › peer-review

ASJC Scopus subject areas

@article{1b0a3603ec7543708ac58365b59fbbff,

title = "A second-generation TKI should always be used as initial therapy for CML",

author = "Cortes, {Jorge E.}",

year = "2018",

month = dec,

day = "26",

doi = "10.1182/bloodadvances.2018018655",

language = "English (US)",

volume = "2",

pages = "3653--3655",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "24",

}

TY - JOUR

T1 - A second-generation TKI should always be used as initial therapy for CML

AU - Cortes, Jorge E.

PY - 2018/12/26

Y1 - 2018/12/26

UR - http://www.scopus.com/inward/record.url?scp=85059234769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059234769&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018018655

DO - 10.1182/bloodadvances.2018018655

M3 - Article

C2 - 30587494

AN - SCOPUS:85059234769

SN - 2473-9529

VL - 2

SP - 3653

EP - 3655

JO - Blood Advances

JF - Blood Advances

IS - 24

ER -